Focus on pipeline expansion and MedTech performance

Johnson & Johnson is confident in its ability to replace the lost revenue from Stelara with other products in its pipeline, without the need to acquire another company. The company has identified ten assets that have the potential to generate more than $5 billion in peak year sales. Additionally, the MedTech segment has demonstrated stellar performance, with consistent growth and a competitive position in the market. The company's clinical trials are progressing well, focusing on areas such as bladder cancer, lung cancer, and multiple myeloma. Furthermore, Johnson & Johnson's use of AI in MedTech shows promise, enhancing productivity, predictive analytics, and surgical procedures, and potentially leading to more insightful clinical data analysis.